Adello’s Filgrastim Biosimilar Faces Infringement Lawsuit And Potential Regulatory Delay
Executive Summary
US FDA user fee date for privately held company’s 351(k) application referencing Amgen’s Neupogen may have passed without word of a regulatory action; Amgen sued Adello in March alleging infringement of 17 patents covering the innovator product.
You may also be interested in...
US FDA Biosimilar User Fee Collections, Expenditures Hit A High Point In 2017
For the first time since the biosimilar user fee program began, FDA spent more in fees than it collected, and more than it spent in appropriated funds.
Biosimilar Legal Landscape: Lessons From 2017
In several firsts last year, US Supreme Court ruled on BPCIA, Amgen won a damages award in infringement litigation, and Amgen and Mylan inked deals clearing way for future launch of Humira and Herceptin biosimilars. Chart includes status of 15 cases and questions teed up for courts to tackle in 2018.
US Supreme Court Permits Earlier Biosimilar Launches; Penalty For Declining Patent Dance Uncertain
Court says biosimilar sponsors may provide 180-day notice of marketing prior to FDA approval; Federal Circuit to decide if innovators can seek an injunction under state law if sponsors do not provide application and manufacturing information; Justice Breyer offers FDA invitation to weigh in.